Are We Drugging the Fish Instead of Cleaning the Tank?

Are we treating symptoms or the disease?

The rise of Ozempic and related GLP-1 drugs—developed for type 2 diabetes and now widely used for weight loss—has forced a harder look at how American healthcare responds to chronic metabolic illness. These medicines help many people. They can lower blood sugar, reduce appetite, and produce meaningful weight loss. That is real.

The question I keep coming back to is whether a mass pivot to injectable symptom management is a substitute for fixing the environment that produces the disease in the first place.

The problem isn’t a lack of Ozempic

CDC figures often cited in public health reporting put adult obesity near roughly 42% in the U.S., with prediabetes affecting a large share of adults—often cited in the ballpark of one in three. Childhood rates have been climbing as well. These are not cosmetic statistics. They are markers of metabolic dysfunction shaped by what we eat, how we move, sleep, and stress, and by policies that make ultra-processed food the default.

I keep coming back to a dirty fish tank. When the fish get sick, you can dose them with medicine—or you can clean the water. Both can matter in an emergency. Only one fixes the system.

Root causes include food environments stacked toward calorie-dense, nutrient-poor products; agricultural and subsidy structures that favor commodity crops and processed ingredients; limited access to affordable whole foods in many communities; and lifestyles built around sitting. A weekly injection can blunt appetite and improve labs for some people. It does not rewrite that environment.

A useful tool—not a miracle substitute for prevention

GLP-1 agonists are not placebos. For people with obesity or type 2 diabetes who have struggled under standard care, they can be life-changing. The risk is treating them as the primary public response to a population-level crisis—and understating the tradeoffs.

Gastrointestinal side effects. Reports and patient data suggest a substantial share of users—often cited around 30%—discontinue within a few months because of nausea, vomiting, or other GI problems. Severe outcomes such as gastroparesis have been reported, and media coverage (for example, USA Today) has tracked emerging lawsuits over long-term digestive issues. Those claims are for courts and regulators to adjudicate. They are still a signal that “set and forget” is not how these drugs work in practice.

Mental health scrutiny. European regulators have examined reports of mood changes and suicidal ideation associated with GLP-1 drugs. Coverage (including CNBC) has linked the concern partly to gut–brain pathways—much of the body’s serotonin is produced in the gut—though causality is not settled. The right response is careful monitoring and honest counseling, not dismissal or panic.

Weight regain after stopping. Clinical and academic reporting has emphasized that many people regain weight when they stop the medication. That does not mean the drug “failed.” It means appetite and metabolic set points reassert themselves when the pharmacological pressure is removed. Framing lifelong injection as the only durable answer should be a policy debate, not an assumed default.

Market focus. Reporting (for example, Bloomberg) has noted that commercial emphasis on obesity indications has been especially intense in the U.S. market relative to other regions. That pattern fits a system where high drug prices, fragmented prevention, and disease-as-profit dynamics amplify pharmaceutical solutions.

I want to be clear: none of this is an argument that patients who use GLP-1s are making a wrong or weak choice. Individual care is not the same as system design. My critique belongs on the system that offers shots more readily than it reforms the food supply, primary care, and incentives.

Who sets the defaults

When a drug class becomes a cultural and clinical default, it is worth asking who shapes the narrative.

Guidelines and research funding. The American Academy of Pediatrics’ willingness to place anti-obesity pharmacotherapy high in the care pathway for adolescents—discussed critically in outlets such as The Atlantic—sparked debate about how early and how aggressively to medicate kids versus intensifying lifestyle and environmental supports. Separately, investigative reporting (including Reuters) has documented industry payments to obesity specialists and institutions. Financial relationships do not automatically invalidate science, but they do require transparent disclosure and independent scrutiny—especially when children’s care is involved.

Advertising and media. Pharmaceutical companies are among the largest spenders on U.S. television advertising. Analyses from academic centers raise a fair question: does pervasive marketing shape which questions get asked on air, and which get soft-pedaled?

Lobbying and framing. Public discussion—including commentary amplified by health policy voices such as Calley Means—has described industry-backed advocacy that frames broader access to anti-obesity drugs in equity or civil-rights terms, including through partnerships with advocacy organizations. Expanding access for people who need treatment can be legitimate. Using moral language to short-circuit debate about prevention and root causes is a different move—and one the public should be able to examine openly.

What I’d actually do

We can hold two truths at once: GLP-1 drugs are a powerful tool for many patients, and a society that mainly drugs its way out of metabolic disease is failing at prevention.

1. Prioritize prevention. Scale public health that makes healthy defaults easier—food policy, school and workplace environments, safe places to move, and access to real food. Rethink agricultural subsidies and incentives that disproportionately advantage ultra-processed supply chains over produce and whole foods.
2. Confront conflicts of interest. Strengthen guardrails on industry funding of guideline-writing bodies, continuing medical education, and “key opinion leader” networks. Independent research funding and clearer disclosure will not eliminate bias, but they reduce the fog.
3. Empower patients without moralizing. Care should still center lifestyle—nutrition, movement, sleep, stress, community—as first-class interventions, with medication as one option among others when clinically appropriate. People deserve informed consent about side effects, duration of therapy, cost, and the likelihood of regain if they stop—not a sales pitch or a lecture.

Bottom line

A healthcare system that only treats the fish while the tank stays dirty will always need more drugs. We should keep effective medicines available to people who need them—and stop pretending that is the same as solving the metabolic crisis.

If you use a GLP-1 yourself, you are not the villain in this story. The unfinished work is upstream—in the tank we all share.